U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H36F2O5
Molecular Weight 478.5685
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIFLUCORTOLONE VALERATE

SMILES

[H][C@@]12C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])C[C@H](F)C4=CC(=O)C=C[C@]34C

InChI

InChIKey=HHJIUUAMYGBVSD-YTFFSALGSA-N
InChI=1S/C27H36F2O5/c1-5-6-7-23(33)34-14-21(31)24-15(2)10-17-18-12-20(28)19-11-16(30)8-9-26(19,4)27(18,29)22(32)13-25(17,24)3/h8-9,11,15,17-18,20,22,24,32H,5-7,10,12-14H2,1-4H3/t15-,17+,18+,20+,22+,24-,25+,26+,27+/m1/s1

HIDE SMILES / InChI

Molecular Formula C27H36F2O5
Molecular Weight 478.5685
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Diflucortolone (used in the form of valerate prodrug) is a corticosteroid developed for the treatment of inflammatory skin diseases. It is supposed that Diflucortolone acts by inducing Annexin A1, a phospholipase A2 inhibitory protein, and thus controls the biosynthesis of prostagladins and leukotrienes. The drug is marketed as a cream under the tradename Nerisone.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NERISONE

PubMed

Sample Use Guides

In Vivo Use Guide
Apply a thin layer and gently rub in using only enough to cover the affected area once or twice a day for a maximum of 4 weeks.
Route of Administration: Topical
In Vitro Use Guide
In the vasoconstriction test on human skin, in which hyperemia has been experimentally induced, a water/oil emulsion with 0.001% diflucortolone valerate is as effective as a similar preparation containing 0.1% fluocortolone.
Substance Class Chemical
Record UNII
1A63Z067C8
Record Status Validated (UNII)
Record Version